When you join OncoSHARE, you become a member of an active network gathering together more than 13 000 patients and oncologists.
Regardless of whether the information concerns patient health or payment, we take every precaution to ensure your security. OncoSHARE is used by oncologists to order our solutions, to display interactive analysis reports and to connect health care professionals to each other and to our team of experts.
In a simple, interactive manner, OncoSHARE will guide you in your selection of the most appropriate treatment options based on the unique signature of your patient’s tumour.
Ordering one of our solid or liquid biopsy solutions is very simple through OncoSHARE, a highly secured platform.
Once we receive your order, we will send you a DHL shipment kit with a prepaid return air waybill and all the necessary material and documents for the shipping back to OncoDNA. Within a few days, we will get the tumour or blood sample and start the analysis.
A comprehensive and integrated report will be available after 7 to 10 days (depending on the test ordered). In a simple and interactive manner, it will guide you in selecting the most appropriate treatments based on the unique signature of the tumour.
Key findings from the different tests, simplified pathway analyses and treatment recommendations based on molecular and clinical evidence.
List of treatments associated with potential clinical benefit, potential lack of clinical benefit, undetermined clinical benefit and toxicity for each patient. Moreover, we provide you with the trade names, therapeutic classes, official indications and the approval status per cancer type.
List of the clinical trials associated with certain molecular features of the patient's tumour.
List of all references used in the report and related to the patient’s molecular profile.
• High definition image of the tumour sample
• Clinical form with patient clinical data
• Cancer type and stage
• Complete list of variants and their biological and therapeutical impact
• List of genes sequenced
• MSI (microsatellite instability)
• TMB (tumour mutational burden)
• Alpha list: Biomarkers associated with FDA and/or EMA approved drugs with pharmacogenomic information on their labels, as well as variants associated with clinical resistance or sensitivity to FDA/EMA approved drugs
• Immunohistochemistry tests
• Unusual splicing and methylation
• Translocations or fusions
The immunogram shows the potential response of each patient to immunotherapy. It is created from (1) the percentage of PD-L1-positive tumor cells, (2) the percentage of infiltrated CD8+ T cells, (3) the level of tumour mutational burden, (4) the microsatellite stability status of the tumour, and (5) the presence of mutations associated with either sensitivity or resistance to immunotherapy
OncoDEEP analyses solid biopsies by combining next-generation sequencing (313 genes), IHCs to study protein expression and additional tests. This complete tumor profiling allows to predict patient response to approved or experimental targeted drugs, hormonal therapies, immunotherapies and chemotherapies. The NGS panel is accurately designed according to oncologists’ needs in their current practice. Importantly, it includes an accurate determination of MSI, TMB and LOH. The NGS panel is regularly updated based on new findings reported in the literature in order to provide patients with the most cost-effective solution.Read more
OncoSTRAT&GO is an integrated approach that combines the analyses of a solid biopsy (by next-generation sequencing (313 genes), IHCs and additional tests) with the analysis of a blood biopsy. The blood profiling focuses either on the circulating tumor DNA (for deciphering tumor heterogeneity) or in DNA from blood cells (for studying specific germline gene alterations related to BRCAness phenotype that are challenging to detect in FFPE samples). OncoSTRAT&GO establishes a complete genetic profile of the tumor, which can be used to identify sensitivity or resistance to targeted therapies, hormonal therapies, chemotherapies and immunotherapies.Read more
OncoSELECT is a fast and minimally invasive analysis of circulating tumor DNA from a blood sample. It is the perfect solution to identify therapeutic options for cancer patients not able to have their tumor biopsied or whose biopsy is too old. It can be used as a tool to detect treatment resistance to targeted and hormonal therapies (before first-line to check the heterogeneity of the disease, or during/after treatment to check for acquired resistance mutations), as well as for monitoring cancer progression.Read more
Our monitoring solution is a test based on the analysis of circulating tumor DNA in blood. It is used to monitor the progression of the tumor (burden of the disease) and to detect lack of response or resistance to treatment as soon as it appears.
This assay is customized for each patient, as it analyses variants previously identified in the tumour of the patient.
In 2013, OncoDNA became the first company to launch a personalised liquid biopsy test.Read more